MarketCap
Facebook
X
Telegram
Oncorus General and Administrative Expenses | ONCR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Oncorus
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 M | 20.1 M | 10 M | 7.12 M | 6.04 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 M | 6.04 M | 13 M |
Quarterly General and Administrative Expenses Oncorus
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.5 M | - | 5.21 M | 6.16 M | 5.35 M | - | 5.44 M | 4.89 M | 4.22 M | - | 1.97 M | 2.01 M | 2.05 M | - | 1.51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.16 M | 1.51 M | 3.94 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
14 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
22 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
36.6 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
92 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
29.9 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
38.8 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
33.3 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
22.2 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
22.5 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
91.6 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
25.2 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
39.6 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
30.7 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
31.2 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
7.48 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
14.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
28.8 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
71.1 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
18.8 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
15.6 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
20.2 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
176 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
50.4 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
17 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
504 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
28.2 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
36.3 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
21 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
24.6 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
131 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
10.7 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
35.4 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
16.2 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
16.6 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
2.18 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
19.7 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
240 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
13 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
11 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
5.42 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
1 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
21.5 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
OncoSec Medical Incorporated
ONCS
|
11.2 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
12.7 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
12.2 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
49.1 M | - | 1.02 % | $ 90.8 M | Britain |